Oxidative stress is involved both in metabolic syndrome and male infertility. Hypogonadism is also associated with increased risk for cardiovascular disease. To investigate the role of gonadal steroids in systemic antioxidants regulation, we determined plasma CoenzymeQ 10 (CoQ 10 ) and Total Antioxidant Capacity (TAC) in post-surgical hypopituitaric patients. Twenty-six patients, aged 28-55 ys, were studied 6-12 months after operation. CoQ 10 levels were measured by HPLC; TAC by spectroscopy using the system mioglobin-H 2 O 2 , which, interacting with the chromogen 2,2 I -azinobis-(3-ethylbenzothiazoline-6-sulphonate),
Introduction
From cross-sectional studies in healthy men, lower plasma total testosterone levels seem to be associated with hyperinsulinemia, decreased glucose tolerance, and a higher level of cardiovascular risk factors (Simon et al., 1992; Haffner b et al., 1994) . A relatively low blood concentration of testosterone in the older men may have adverse effects promoting atherosclerosis and explain the higher incidence of coronary heart disease in the male . Therefore, male hypogonadism can be associated with metabolic syndrome as well as increased risk for cardiovascular disease.
Oxidative stress, due to an imbalance between reactive oxygen species (ROS) and antioxidant defense, can underlie both these phenomena. However the role of gonadal steroids in the regulation of systemic antioxidants is not known.
It has already been recognized that seminal Total Antioxidant Capacity (TAC), which reflects non enzymatic antioxidants, significantly correlates with FSH, LH, free-T3 (fT3), but not with testosterone (Mancini et al., 2005) . In previous works we have demonstrated alterations of plasma coenzyme Q 10 (CoQ 10 ), a lipidic antioxidant, also endowed with bioenergetic properties, in pituitary diseases, such as acromegaly or secondary hypothyroidism. In particular, in patients with acromegaly, plasmatic value of CoQ 10 was low; in hypothyroidism CoQ 10 levels were higher than controls, showing a significant inverse correlation with thyroidal hormones, fT3 and free-T4 (fT4) (Mancini et al., 1987; Mancini et al., 1991; Mancini et al., 1992) .
Finally, a relationship between sex hormones and plasmatic TAC was already observed (Demirbarg et al., 2005) . In fact, estradiol correlated with TAC, that showed lower levels in post-menopausal women than in pre-menopausal ones. Similarly in men testosterone correlated with TAC, that was lower in hypogonadal men than normogonadal ones. The exact molecular mechanism of this action is not known, but estrogens are potent antioxidants both in vitro and in vivo (Avres et al., 1996) , especially in terms of protection of fatty acid peroxidation. Both testosterone and estradiol were shown to increase the effects of antioxidant enzymes, such as glutathione peroxidase (Massafra et al., 2000) . In vivo, significant cycle-phase related changes in this enzyme were observed in cycling women with positive correlation between estradiol and erythrocyte glutathione-peroxidase (Massafra et al., 1998) .
In order to investigate the role of gonadal steroids in the regulation of systemic antioxidants, we determined blood plasma CoQ 10 and TAC in a group of hypopituitaric patients, following a trans-sphenoidal removal of non-secreting pituitary adenoma or craniopharyngioma. The first objective was to compare hypogonadal patients to normogonadal ones. However, due to the complexity of this postoperative model and the involvement of different pituitary-dependent axes, in order to explain the confounding effect of hypothyroidism on antioxidants, patients with hypothyroidism and hypogonadism were compared to patients with isolated hypogonadism. Finally, the effect of testosterone replacement therapy was evaluated in patients with isolated hypogonadism.
Subjects, Materials and Methods
Twenty-six male subjects, aged 28-55 years, entered this study, after they had given an informed consent.
The study was conducted in accordance with the guidelines in the Declaration of Helsinki. The patients were studied at 6-12 months after neurosurgical operation via trans-sphenoidal route, with removal of a nonsecreting pituitary adenoma or craniopharyngioma. All patients were hypopituitaric, with replacement therapy for thyroidal (ranging from 50 to 100 mcg of L-thyroxine daily according to body weight) and adrenal (20-30 mg of hydrocortisone daily) axes. Patients were classified as normo-or hypogonadal according to their testosterone levels; no androgen replacement therapy had been previously performed before the study. Exclusion criteria for our study included diseases with well-known decreased levels of CoQ 10 : cardiac, metabolic, cerebral, neuromuscular and mitochondrial diseases (Thomas et al., 2001; Singh and Narankar, 2003; Yalcin et al., 2004; Koroshetz et al., 1997; Beal and Russel, 1997) . In the second step, when comparing data before and after androgen therapy, a further added exclusion criterion was the persistence of abnormal thyroid hormones values, because of the demonstrated predominant confounding effect of both hypo-and hyperthyroidism (Mancini et al., 1991) .
A blood sample was collected at 08.00 am, for the determination of testosterone (T) , estradiol (E2), dihydrotestosterone (DHT), sex hormone binding globulin (SHBG), luteinizing hormone (LH), folliclestimulating hormone (FSH), free-T3 (fT3), free-T4 (fT4), thyroid-stimulating hormone (TSH), prolactin (PRL), insulin-like growth factor 1 (IGF-1), CoQ 10 , total cholesterol levels, and TAC in blood plasma. After centrifugation at 2000 g for 10 min, plasma aliquots were immediately stored at -80°C, until assayed.
Finally, urinary cortisol (F U ) was assayed in a sample from 24-hour collection.
Moreover, patients with isolated hypogonadism were also studied after a six-month treatment with testosterone enantate (250 mg/im every 3 weeks). Blood collection in testosterone-treated group was performed at the 7 th day after the last testosterone enantate injection, according to the kinetic profile of the drug.
Testosterone, estradiol, prolactin and thyroid hormones were assayed in duplicate by RIA, using commercial kits by Radim (Pomezia, Italy). LH, FSH and SHBG were assayed by immunoradiometric method on solid phase (coated tube), which is based on a monoclonal double-antibody technique.
Dihydrotestosterone and urinary cortisol were assayed by RIA, using commercial kits by Chematil (Angri, Italy). Plasma IGF-1 was measured by immunoradiometric assay method using kits from Medgenix Diagnostix SA (Fleurus, Belgium); soluble IGF-1 was separated from interfering binding proteins using the acid-ethanol procedure of Daughaday (Daughaday et al., 1980) . Free testosterone (free-T) was calculated using the formula proposed by Vermeulen (Vermeulen et al., 1999) .
Normal values of the studied hormones were for testosterone: 12.14-34.67 nmol/L; free-T 174-902 pmol/L; for TSH, 4.9% for fT4, 3.9% for fT3, 3.1 for PRL, 8.9% for F U, 9,6% for IGF-1.
CoQ 10 levels were measured by a well recognized HPLC (high-performance liquid chromatography) method (Mosca et al., 2002) . The method is based on oxidation of CoQ 10 in the sample by treating it with para-benzoquinone followed by extraction with 1-propanol and direct injection into the HPLC apparatus. Total Antioxidant Capacity (TAC) was evaluated as previously described (Meucci et al., 2003) , with a modification of the method developed by Rice-Evans and Miller (Rice-Evans and Miller, 2004) . The method is based on the antioxidants inhibition of the absorbance of the radical cation 2,2 I -azinobis (3-ethylbenzothiazoline-6 sulphonate) (ABTS .+ ) formed by interaction between ABTS (150 μM ) and ferrylmyoglobin radical species, generated by activation of metmyoglobin (2.5 μM ) with H 2 O 2 ( 75 μM).
Aliquots of the frozen plasma were thawed at room temperature and 10 μl of the samples were tested immediately. The manual procedure was used with only minor modifications, i.e. temperature was set at 37°C, to be in more physiological conditions, and each sample was assayed alone to carefully control timing and temperature. The reaction was started directly in a cuvette through H 2 O 2 addition after 1 min equilibration of all other reagents (temperature control by a thermocouple probe, model 1408 K thermocouple, Digitron Instrumentation Ltd, Scunthorpe, United kingdom) and followed for 10 min under continuous stirring, monitoring at 734 nm, typical of the spectroscopically detectable ABTS .+
. The presence of chain-breaking antioxidants induces a lag time (the LAG phase) in the accumulation of ABTS .+ whose length (sec) is proportional to the concentration of this type of antioxidants. In the LAG mode, the assay mainly measures non-protein and non-enzymatic antioxidants that are primarily extracellular chain-breaking antioxidants, such as ascorbate, urate and glutathione (Meucci et al., 2003) . Trolox, a water-soluble tocopherol analog, was used as a reference standard and assayed in all experiments to control the system. 
Results
Sixteen of the twenty-six hypopituitaric patients presented low levels of testosterone, which were instead normal in the remaining ten patients. CoQ 10 and LAG were lower, although not significantly, in hypogonadal patients than in normogonadal ones (see Table 1 ).
The 16 hypogonadic patients also needed replacement therapy for secondary thyroidal and adrenal deficiencies; normal Igf-1 values indicated preservation of GH-Igf-1 axis. Despite thyroidal replacement therapy, at the time of the study, only ten hypogonadal patients exhibited a normalization of thyroidal values, while six hypogonadal patients remained hypothyroidal (see Table 2 ); all the patients showed normal cortisol levels under replacement therapy. When we divided hypogonadal patients in normo-and hypothyroidal, we found a significantly lower CoQ 10 value in isolated hypogonadism (see Table 2 ); CoQ 10 in isolated hypogonadism was also significantly lower than in normogonadal subjects (p < 0.05). When the concentrations of CoQ 10 were normalized to cholesterol values, the trend was the same, but the difference among the groups was not significant (see Table 2 ).
CoQ 10 and CoQ 10 /Cholesterol significantly correlated with LAG values (r = 0.5, p < 0.005 and r = 0.7, p < 0.001, respectively), suggesting an inter-relationship between different antioxidants in the whole group of patients (see Figure 1) .
Because of the confounding role of thyroid hormones, the study continued only on patients with isolated hypogonadism, who underwent testosterone enantate replacement therapy. Testosterone treatment, by restoring a normogonadal state, induced a significant change both in CoQ 10 concentration (937.62 ± 32.79 nmol/L) and in LAG values (78 ± 3 s) (see Figure 2) . CoQ 10 /Cholesterol ratio did not significantly change, confirming that CoQ 10 variations were not only due to alteration in CoQ 10 transport in plasma lipoproteins.
Discussion
The physiology of testosterone is complex. Its blood concentration shows a circannual and circadian variation and the biologically active moiety is affected by both the amount of sex hormone binding globulin (SHBG) and albumin. The concept of "bioavailable" testosterone, which comprises free testosterone (1-2% of total) and that component loosely bound to albumin, has led to a more accurate assessment of the androgen status. Moreover, because testosterone is converted to estrogen by the aromatase enzyme in adipose tissue, an individual's concentration is affected by body habitus and weight ). There is a higher incidence of men with low testosterone concentrations as age progresses (Vermeulen et al., 1972) .
Epidemiological observations suggest a relationship between hypogonadism and cardiovascular diseases.
Recent studies have shown that men with coronary artery disease (CAD) have significantly lower concentrations of bioavailable testosterone than men with normal angiograms (English et al., 2000) . The prevalence of hypogonadism in a population of men with CAD is about twice that observed in the general population (Morris et al., 2002) . Hypotestosteronemia is associated with an atherogenic lipid profile (elevated low density lipoproteins and triglycerides, decreased high density lipoprotein), high fibrinogen with a hypercoagulable state, an increase in insulin resistance and hyperinsulinaemia, and higher systolic and diastolic blood pressure (English et al., 1997) .
Also experimental data reinforce the concept of a positive effect of exogenous testosterone administration. In an animal model, castration increased aortic atheroma formation and testosterone replacement ameliorated this effect (Alexandersen et al., 1999) . In addition, testosterone has direct vasoactive properties, which directly affect the vascular smooth muscle, not mediated by the nuclear androgen receptor, as the effect is too rapid and is not reduced by flutamide, a nuclear androgen receptor blocker (English et al.,2001; English et al., 2002; Deenadayalu et al., 2001) . When testosterone is instilled into the left coronary artery, vasodilatation ensues and coronary flow increases (Webb b et al., 1999) . More importantly, acute administration of intravenous testosterone improves exercise tolerance and reduces angina threshold in men with CAD (Rosano et al., 1999; . These positive effects seem to be related to the nongenomic action of testosterone on vascular smooth muscle cells Jones b et al., 2003) .
Oxidative stress can underlie the above mentioned clinical conditions. As demonstrated by statistical meta-analysis, low testosteronemia and androgen deficiency were associated with increased risk of developing metabolic syndrome over time (Kupelian et al.,2006) . However, the pathophysiological details of these changes in atherosclerosis (Von Eckardstein and Wu, 2004) and implications in testosterone replacement therapy (Nieschlag et al.,2004) are still under investigation. Moreover the role of gonadal steroids in the regulation of systemic antioxidants is not known. We therefore investigated the role of CoQ 10 , a lipidic antioxidant, and of TAC of blood plasma in secondary male hypogonadism.
Coenzyme Q 10 is well defined as a crucial component of the oxidative phosphorylation process in mitochondria. It can undergo oxidation/reduction reactions in other cell membranes such as lysosomes, Golgi or plasma membranes. The presence of high concentrations of quinol in all membranes provides a basis for antioxidant action either by direct reaction with radicals or by regeneration of tocopherol and ascorbate (Crane and Frederick, 2001) . Evidence for a function in redox control of cell signalling and gene expression can be found in studies on coenzyme Q stimulation of cell growth, inhibition of apoptosis, control of thiol groups, formation of hydrogen peroxide, and control of membrane channels (Groneberg et al.,2005) . Thyroid hormones exert a profound influence on CoQ 10 , as previously demonstrated (Mancini et al., 1991) .
Hyperthyroid patients exhibit extremely low CoQ 10 levels. The possible mechanisms include: a) decreased synthesis, related to the competition for tyrosine, which is common substrate for CoQ and thyroxine synthesis (Olson, 1983) , even if this hypothesis is disconfirmed by experimental data in animals (Ikeda et al., 1984; Horrum et al., 1986) ; b) increased CoQ 10 utilization, due to the increased stimulation of energy metabolism; c) increased degradation; d) decreased levels of carriers in serum, since it has been demonstrated that the VLDL release from liver is decreased in hyperthyroid states (Keyes et al., 1981) . The opposite mechanisms could explain higher CoQ 10 levels in hypothyroidism.
Another important parameter of the antioxidant defense of body is plasmatic TAC, which is studied with greater frequency. Representing the functional sum of antioxidants present in plasma, it is a measure of the extracellular antioxidant barrier (Prior and Cao, 1999; Bartoz, 2003; Chevion and Chevion, 2000) . In a recent work, TAC was determined during cardiovascular bypass surgery in patients with coronary heart disease:
TAC decreased during surgery, but no further decrease in TAC was observed during reperfusion, indicating that it is a relatively stable parameter of the antioxidant barrier of the body (Kedziora-Kornatowska et al., 2003) . Finally, a relationship between sex hormones and plasmatic TAC had already been observed (Demirbag et al.,2005) . In this paper TAC was measured with a novel automatized method (Erel, 2004) .
When expressed as mmol Trolox equivalent/L, it significantly correlated with total testosterone in male subjects and also with estradiol in a group of pre-and post-menopausal women (Demirbag et al.,2005) . No effect of androgens was observed on erythrocyte antioxidant systems in cycling women (Massafra et al., 2000) .
Conflicting results do not allow unequivocal conclusions on the role of androgens in coronary artery disease, as recently reviewed by Wu and Liu (Wu and von Eckardstein, 2003; Liu et al., 2003) . Many confounding factors contribute to making this question a very complex one. Studies on endogenous androgen levels depend on different mechanisms, such as gender-specific gene expression, distribution of body fat, vascular factors, and adaptation to ageing. Similarly, studies on exogenous androgen administration are influenced by dose, route of administration, duration of treatment and again gender, age, condition of recipients. Moreover, the field of androgen effects on cardiovascular system, concerning genomic and nongenomic effects, aromatization-mediated or not actions, anti-and pro-atherogenic mechanisms is rapidly growing, but it still does not allow a conclusive picture. Therefore, data on antioxidant regulation by steroids can be useful to clarify molecular mechanisms of testosterone action.
Even though the relationship between systemic and seminal antioxidants, as well as systemic regulation of seminal antioxidants, are still poorly understood, our data suggest that CoQ 10 levels are significantly lower in secondary isolated hypogonadal vs normogonadal patients with the same physiopathological postoperative condition. However, since thyroid hormones have an important role in modulating CoQ 10 levels and metabolism (Mancini et al., 1991) , when coexistent, thyroid deficiency could be more important in influencing antioxidant levels than hypogonadism. Other explanations such as thyroid influence on gonadal hormones are unlikely in this particular clinical model. It is well known that hypothyroidism per se reduces the clearance of testosterone and increases SHBG (Larsen and Davies, 2003) , but these mechanisms are not relevant in our model where both axes are depressed due to the pituitary surgery. The same consideration concerns the possible effects of hypothyroidism on GnRH secretion (Toni et al., 2005) , and on Leydig cell steroidogenesis (Mendis-Handagama and Siril Ariyaratne, 2005) . The influence of pituitary-adrenal axis and of growth hormone, which can affect antioxidant levels (Mancini et al., 2005; Brown-Borg et al., 1999) were excluded on the basis of normal cortisol and IGF-1 levels.
Testosterone therapy reported values toward the same levels observed in normogonadic patients, with a significant increase in CoQ 10 concentrations. TAC also, expressed as LAG, which exhibited a trend toward lower values in hypogonadal subjects, was significantly increased by testosterone treatment.
In conclusion, our data reinforce the concept that hypogonadism could represent a condition of oxidative stress. Although the small number of patients studied does not allow definitive conclusions, lower levels of CoQ 10 were discovered in isolated hypogonadal vs normogonadal patients. To our knowledge this is the first report of testosterone effect on antioxidant systems in humans. Further studies can clarify the relationship of this datum with the augmented cardiovascular risk in such patients. 
